Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Covington
Deloitte
Cantor Fitzgerald
McKinsey
Fuji

Generated: August 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,404,087

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,404,087
Title:Insulin producing cells derived from pluripotent stem cells
Abstract: A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.
Inventor(s): Revel; Michel (Rehovot, IL), Chebath; Judith (Rehovot, IL), Slutsky; Guy (Holon, IL), Levy; Alon (Ramat-HaSharon, IL), Izrael; Michal (Rehovot, IL), Hasson; Arik (Kiryat-Ono, IL), Molakandov; Kfir (Yahud, IL), Kaufman; Rosalia (Rehovot, IL)
Assignee: Kadimastem Ltd. (Nes-Ziona, IL)
Application Number:13/989,805
Patent Claims:1. A method of generating human islet cells or human islet progenitor cells from human pluripotent stem cells and selecting for insulin producing cells, the method comprising: (a) culturing the human pluripotent stem cells for a period ranging from 5 to 8 days in a differentiation medium comprising glucose so as to differentiate the human pluripotent stem cells into endoderm cells expressing Sox17 and FoxA2; (b) after obtaining said endoderm cells, culturing said endoderm cells for a period ranging from 2 to 10 days in a medium comprising forskolin, retinoic acid, glucose and at least one growth factor, the least one growth factor selected from the group consisting of FGF10,bFGF and FGF7 so as to generate PDX-1 positive cells; (c) culturing said PDX-1 positive cells in a medium comprising glucose and at least one maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells or islet progenitor cells from pluripotent stem cells; wherein the generating of human islet cells or human islet progenitor cells is effected without the generating of embryoid bodies; (d) dispersing said islet cells or islet progenitor cells to generate dispersed human islet cells or dispersed human islet progenitor cells; (e) contacting said islet cells or islet progenitor cells with an agent that binds to EpCAM; (f) selecting cells which bind to said agent; thereby generating human islet cells or human islet progenitor cells that produce insulin; and (g) reaggregating said dispersed human islet cells or dispersed human islet progenitor cells that produce insulin.

2. The method of claim 1, wherein said differentiation medium comprises activin A.

3. The method of claim 2, wherein said differentiation medium comprises serum or serum replacement substitute.

4. The method of claim 2, wherein said differentiation medium is devoid of serum.

5. The method of claim 4, wherein said medium of step (b) further comprises noggin.

6. The method of claim 2, wherein said differentiation medium further comprises Wnt3.

7. The method of claim 1, wherein said culturing the pluripotent stem cells is effected by culturing collagenase-detached clusters of pluripotent stem cells on a gelatin coated surface.

8. The method of claim 1, wherein the human pluripotent stem cells comprise human induced pluripotent cells (iPP) cells.

9. The method of claim 1, wherein said re-aggregating is effected in a presence of an agent that chelates calcium selected from the group consisting of EDTA, EGTA, BAPTA, citrate, and phosphate.

10. The method of claim 1, further comprising seeding said dispersed islet cells on a scaffold.

11. The method of claim 1, wherein said re-aggregating is effected in a medium comprising glucose which is lower than that used in steps (a), (b) or (c).

12. The method of claim 1, wherein a glucose concentration of each of said media is between 5 mM-100 mM.

13. The method of claim 1, wherein the islet cells are glucose responsive, and synthesize insulin, glucagon or somatostatin.

14. The method of claim 1, wherein said endoderm cells do not express Oct4.

15. The method of claim 1, wherein step (a) or (b) is effected for about 5 days.

16. A population of islet cells or islet progenitor cells generated according to the method of claim 1.

17. A pharmaceutical composition comprising the population of cells of claim 16 as an active ingredient and a pharmaceutically acceptable carrier.

18. A method of treating diabetes in a subject in need thereof, the method comprising transplanting a therapeutically effective amount of the population of cells of claim 16 into the subject, thereby treating the diabetes.

19. The method of claim 1, wherein the culturing of said PDX-1 positive cells of step further comprises a maturation factor, wherein said maturation factor is nicotinamide, exendin 4, or a combination thereof.

Summary for Patent: ➤ Sign Up

PCT Information
PCT FiledDecember 15, 2011PCT Application Number:PCT/IL2011/050068
PCT Publication Date:June 21, 2012PCT Publication Number:WO2012/081029

Details for Patent 9,404,087

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Kadimastem Ltd. (Nes-Ziona, IL) 2030-12-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
AstraZeneca
Accenture
Harvard Business School
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.